Photofrin as a specific radiosensitizing agent for tumors: studies in comparison to other porphyrins, in an experimental in vivo model

Schaffer, Moshe; Schaffer, Pamela; Corti, L.; Gardiman, Marina Paola; Sotti, Guido; Hofstetter, A.; Jori, Giulio; Dühmke, Eckhart

doi:10.1016/s1011-1344(02)00237-3

Cited by 60 publications

(71 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ROS can damage critical cellular components such as DNA, proteins and lipids, and eventually lead to physical and chemical damage to tissues (23). Some studies speculate that Photofrin may enhance the radiolytic activity by reacting with cytotoxic, activated molecules such as hydroxyl radicals, which are known to be generated as a result of the primary interaction of ionizing radiation with water (24). In the present study, intracellular ROS produced by ionizing irradiation co-localized with 5-ALA-induced PpIX in 9L cells (Fig.…”

Section: -Ala-induced Ppix As a Specific Radiosensitizer In Glioma Cmentioning

confidence: 99%

Radiosensitizing effect of 5-aminolevulinic acid-induced protoporphyrin IX in glioma cells inï¿½vitro

et al. 2012

View full text Add to dashboard Cite

Abstract. 5-Aminolevulinic acid (ALA) is a prodrug used in photodynamic therapy and fluorescence-guided resection of malignant gliomas due to its high cellular uptake in tumours. Porphyrin compounds act not only as photosensitizers but also as radiosensitizers. In the present study, the possible use of 5-ALA as a radiosensitizer for malignant gliomas was examined in vitro. Rat glioma cell lines (9L, C6) were pre-treated with 5-ALA and exposed to ionizing irradiation. The radiosensitizing effect of 5-ALA was evaluated by colony-forming assay. Intracellular reactive oxygen species (ROS) produced by 5-ALA and irradiation were evaluated by confocal laser scanning microscopy. Pre-treatment with 5-ALA enhanced the radiosensitivity of 9L cells to single-dose ionizing irradiation compared with controls (D 0 value, 4.35±0.20 and 4.84±0.23 Gy, respectively, P≤0.05). Exposure to multi-dose ionizing irradiation revealed high radiosensitivity in both 9L and C6 cells pre-treated with 5-ALA compared to controls. Production of intracellular ROS increased in 9L cells pretreated with 5-ALA after ionizing irradiation compared to control cells. Thus, 5-ALA functions as a specific radiosensitizer for malignant gliomas. Intracellular 5-ALA-induced PpIX plays an important role in the production of ROS and the radiosensitizing effect under ionizing irradiation conditions.

show abstract

Section: -Ala-induced Ppix As a Specific Radiosensitizer In Glioma Cmentioning

confidence: 99%

Radiosensitizing effect of 5-aminolevulinic acid-induced protoporphyrin IX in glioma cells inï¿½vitro

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Specifically, the use of Photofrin as a radiosensitizer would be advantageous, since a single chemical agent could be injected and increase the sensitivity of tumor tissue to both ionizing and nonionizing radiation. Several recently published studies on tissue cultures and on murine tumor models have demonstrated the in vitro and in vivo efficacy of Photofrin II as both a specific and a selective radiosensitizing agent [8][9][10][11][12]. These animal studies have assessed the efficacy of the radiosensitizing action in terms of tumor doubling time (∆t), i.e.…”

Section: Introductionmentioning

confidence: 99%

“…The ∆t value was found to be 6.2 days for non-irradiated cancer (control cases) and increased to 10.9 days in the group of mice exposed to a combination of ionizing radiation and Photofrin II. The mechanism of action of Photofrin II as a radiosensitizer is not clear [8][9][10][11][12]. The radiosensitizing process of Photofrin II may involve the oligomeric porphyrin constituents which are enriched in Photofrin [8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Feasibility of Photofrin II as a Radiosensitizing Agent in Solid Tumors – Preliminary Results

Schaffer

Ertl‐Wagner²,

Schaffer

et al. 2006

Oncol Res Treat

View full text Add to dashboard Cite

Photofrin II has been demonstrated to serve as a specific and selective radiosensitizing agent in in vitro and in vivo tumor models. We aimed to investigate the feasibility of a clinical application of Photofrin II. Material and Methods: 12 patients were included in the study (7 unresectable solid tumors of the pelvic region, 3 malignant gliomas, 1 recurrent oropharyngeal cancer, 1 recurrent adenocarcinoma of the sphenoid sinus). The dose of ionizing irradiation was 30-50.4 Gy; a boost irradiation of 14 Gy was added for the pelvic region. All patients were intravenously injected with 1 mg/kg Photofrin II 24 h prior to the commencement of radiotherapy. Magnetic resonance imaging (MRI) controls and in some cases positron emission tomography (PET) were performed in short intervals. The mean follow-up was 12.9 months. Results: No major adverse events were noted. Minor adverse events consisted of mild diarrhea, nausea and skin reactions. A complete remission was observed in 4/12 patients. A reduction in local tumor volume of >45% was achieved in 4/12 patients. Stable disease was observed in 4/12 patients. 1 patient showed local disease progression after 5 months. Conclusion: The early follow- up results are encouraging regarding the feasibility of the application of Photofrin II as a radiosensitizing agent.

show abstract

“…In recent years, researchers have become increasingly interested in combining antitumor therapies in order to improve the patient outcome and to avoid, at least in part, unwanted side effects. In this context, there are reports indicating that some PSs can act as radiosensitizers [8,9] . With regard to breast cancer, several in vitro studies have shown a synergism between PDT and ionizing radiation in killing cells.…”

Section: Pdt Combined With Conventional Breast Cancer Therapiesmentioning

confidence: 99%

Breast cancer as photodynamic therapy target: Enhanced therapeutic efficiency by overview of tumor complexity

Lamberti

Vittar

Rivarola

2014

WJCO

View full text Add to dashboard Cite

Photodynamic therapy is a minimally invasive and clinically approved procedure for eliminating selected malignant cells with specific light activation of a photosensitizer agent. Whereas interstitial and intra-operative approaches have been investigated for the ablation of a broad range of superficial or bulky solid tumors such as breast cancer, the majority of approved photodynamic therapy protocols are for the treatment of superficial lesions of skin and luminal organs. This review article will discuss recent progress in research focused mainly on assessing the efficacies of various photosensitizers used in photodynamic therapy, as well as the combinatory strategies of various therapeutic modalities for improving treatments of parenchymal and/or stromal tissues of breast cancer solid tumors. Cytotoxic agents are used in cancer treatments for their effect on rapidly proliferating cancer cells. However, such therapeutics often lack specificity, which can lead to toxicity and undesirable side effects. Many approaches are designed to target tumors. Selective therapies can be established by focusing on distinctive intracellular (receptors, apoptotic pathways, multidrug resistance system, nitric oxidemediated stress) and environmental (glucose, pH) differences between tumor and healthy tissue. A rational design of effective combination regimens for breast cancer treatment involves a better understanding of the mechanisms and molecular interactions of cytotoxic agents that underlie drug resistance and sensitivity. Key words: Photodynamic therapy; Breast cancer; Tumor microenvironment; Treatment combination; Synergism Core tip: Breast cancer is the most common cancer in women worldwide. However, effective therapies that reduce the high mortality rate and improve patient quality of life are still unavailable. In recent years, the use of photodynamic therapy has been examined for use in breast cancer treatment. Photodynamic therapy provides a new and promising antitumor strategy that could be implemented, alone or in combination with other approved or experimental therapeutic approaches, to a wide range of applications.

show abstract

Photofrin as a specific radiosensitizing agent for tumors: studies in comparison to other porphyrins, in an experimental in vivo model

Cited by 60 publications

References 16 publications

Radiosensitizing effect of 5-aminolevulinic acid-induced protoporphyrin IX in glioma cells inï¿½vitro

Radiosensitizing effect of 5-aminolevulinic acid-induced protoporphyrin IX in glioma cells inï¿½vitro

Feasibility of Photofrin II as a Radiosensitizing Agent in Solid Tumors – Preliminary Results

Breast cancer as photodynamic therapy target: Enhanced therapeutic efficiency by overview of tumor complexity

Contact Info

Product

Resources

About